<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-17687" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Antidepressants</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Sheffler</surname>
            <given-names>Zachary M.</given-names>
          </name>
          <aff>LECOM</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Patel</surname>
            <given-names>Preeti</given-names>
          </name>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Abdijadid</surname>
            <given-names>Sara</given-names>
          </name>
          <aff>UCLA</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Zachary Sheffler declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Preeti Patel declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Sara Abdijadid declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>26</day>
          <month>5</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-17687.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p content-type="pubmed-excerpt">While antidepressants may be the drug of choice for depression, they also have FDA approval as treatments for other medical disorders. For example, antidepressants help treat obsessive-compulsive disorder, social phobia, panic disorder, generalized anxiety disorder (GAD), and post-traumatic stress disorder (PTSD). Antidepressants also have non-FDA-approved, off-label indications. This activity reviews the indications, contraindications, action, adverse events, and other key elements of antidepressant therapy in the clinical setting as it relates to the essential points needed by members of an interprofessional team managing the care of patients receiving antidepressant medications for conditions that respond to this medication class.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify the approved and off-label indications for antidepressant medications.</p></list-item><list-item><p>Summarize the mechanism of action of the various class members in the antidepressant drug class.</p></list-item><list-item><p>Outline the adverse events of various antidepressant medications.</p></list-item><list-item><p>Explain the importance of antidepressant therapy and how it affects therapeutic strategy as a component of care coordination and communication among the interprofessional team when using these agents to achieve therapeutic outcomes.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=17687&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=17687">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-17687.s2" sec-type="Indications">
        <title>Indications</title>
        <p>Depressive disorders include unipolar major depression, persistent depressive disorder (dysthymia), premenstrual dysphoric disorder, and depressive disorder due to another medical condition.&#x000a0;Major depressive disorder (MDD) is one of the most disabling mental illnesses and has significant&#x000a0;morbidity and mortality.&#x000a0;The lifetime prevalence of MDD&#x000a0;ranges from 2 to 21% worldwide. The main sociodemographic correlates were divorced marital status and female gender.<xref ref-type="bibr" rid="article-17687.r1">[1]</xref>&#x000a0;With appropriate treatment, 70&#x000a0;to 80% of individuals with major depressive disorder can significantly reduce symptoms.&#x000a0;Drugs used for the treatment of depression include the following.</p>
        <p>
<bold>Selective Serotonin Reuptake Inhibitors (SSRIs)</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Sertraline</p>
          </list-item>
          <list-item>
            <p>Fluvoxamine</p>
          </list-item>
          <list-item>
            <p>Fluoxetine</p>
          </list-item>
          <list-item>
            <p>Paroxetine</p>
          </list-item>
          <list-item>
            <p>Citalopram</p>
          </list-item>
          <list-item>
            <p>Escitalopram</p>
          </list-item>
        </list>
        <p>
<bold>Serotonin/Norepinephrine Reuptake inhibitors (SNRIs)</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Venlafaxine</p>
          </list-item>
          <list-item>
            <p>Desvenlafaxine</p>
          </list-item>
          <list-item>
            <p>Duloxetine</p>
          </list-item>
          <list-item>
            <p>Milnacipran</p>
          </list-item>
          <list-item>
            <p>Levomilnacipran</p>
          </list-item>
        </list>
        <p>
<bold>Atypical Antidepressants</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Bupropion</p>
          </list-item>
          <list-item>
            <p>Mirtazapine</p>
          </list-item>
          <list-item>
            <p>Agomelatine</p>
          </list-item>
        </list>
        <p>
<bold>Serotonin Modulators</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Nefazodone</p>
          </list-item>
          <list-item>
            <p>Trazodone</p>
          </list-item>
          <list-item>
            <p>Vilazodone</p>
          </list-item>
          <list-item>
            <p>Vortioxetine</p>
          </list-item>
        </list>
        <p>
<bold>Tricyclic Antidepressants (TCAs)</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Amitriptyline</p>
          </list-item>
          <list-item>
            <p>Clomipramine</p>
          </list-item>
          <list-item>
            <p>Doxepin</p>
          </list-item>
          <list-item>
            <p>Imipramine</p>
          </list-item>
          <list-item>
            <p>Trimipramine</p>
          </list-item>
          <list-item>
            <p>Desipramine</p>
          </list-item>
          <list-item>
            <p>Nortriptyline</p>
          </list-item>
          <list-item>
            <p>Protriptyline</p>
          </list-item>
          <list-item>
            <p>Maprotiline</p>
          </list-item>
          <list-item>
            <p>Amoxapine</p>
          </list-item>
        </list>
        <p>
<bold>Monoamine Oxidase Inhibitors (MAOIs)</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Selegiline</p>
          </list-item>
          <list-item>
            <p>Moclobemide</p>
          </list-item>
          <list-item>
            <p>Tranylcypromine</p>
          </list-item>
          <list-item>
            <p>Isocarboxazid</p>
          </list-item>
          <list-item>
            <p>Phenelzine</p>
          </list-item>
        </list>
        <p>
<bold>NMDA Antagonists</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Esketamine- Intranasal esketamine is FDA approved for treatment-resistant depression in adults, in combination with an oral antidepressant. It is also indicated for treating major depressive disorder with suicidal ideation or behavior in adults.<xref ref-type="bibr" rid="article-17687.r2">[2]</xref></p>
          </list-item>
          <list-item>
            <p>The FDA has approved dextromethorphan/bupropion fixed drug combination(FDC) for major depressive disorder. FDA granted dextromethorphan/bupropion breakthrough therapy designation under priority review.<xref ref-type="bibr" rid="article-17687.r3">[3]</xref></p>
          </list-item>
          <list-item>
            <p>Meta-analysis of the comparative efficacy&#x000a0;of&#x000a0;antidepressant results indicates that sertraline and escitalopram have good efficacy with minimal adverse drug reactions than other drugs. Hence sertraline or escitalopram is the initial drug of choice for unipolar major depression.<xref ref-type="bibr" rid="article-17687.r4">[4]</xref></p>
          </list-item>
          <list-item>
            <p>Antidepressants&#x000a0;are the drug of choice for depression, but they also have FDA approval as treatments for other medical disorders. For example, antidepressants are helpful in treating obsessive-compulsive disorder, social phobia, panic disorder, generalized anxiety disorder (GAD), and post-traumatic stress disorder (PTSD).<xref ref-type="bibr" rid="article-17687.r5">[5]</xref>&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Antidepressants also have non-FDA-approved, off-label indications. For example, tricyclic antidepressants are prescribed for pain, insomnia, and migraine. Trazodone, a serotonin modulator, is used off-label for insomnia.<xref ref-type="bibr" rid="article-17687.r6">[6]</xref></p>
          </list-item>
        </list>
      </sec>
      <sec id="article-17687.s3" sec-type="Mechanism of Action">
        <title>Mechanism of Action</title>
        <p>The antidepressants all work slightly differently and target certain neurotransmitters to modulate mood and behavior. All currently licensed antidepressants are believed to increase serotonin, norepinephrine, or both in the synapse. The mechanisms to increase these neurotransmitters vary, though antidepressant drugs target reuptake by the nerve terminals.<xref ref-type="bibr" rid="article-17687.r7">[7]</xref></p>
        <p>
<bold>SSRI</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>The reuptake of 5HT(5-hydroxytryptamine/serotonin) into presynaptic terminals is mediated by SERT;&#x000a0;neuronal uptake is the primary process by which neurotransmission via&#x000a0;5HT is terminated. SSRIs block reuptake and enhance&#x000a0;and prolong serotonergic neurotransmission. With continuous administration of SSRI, there are sustained&#x000a0;increases in cyclic AMP signaling and phosphorylation of the nuclear&#x000a0;transcription factors and increases in the expression of trophic&#x000a0;factors such as BDNF and increased neurogenesis.<xref ref-type="bibr" rid="article-17687.r8">[8]</xref></p>
          </list-item>
          <list-item>
            <p>SSRIs are currently the first-line agents for the treatment of depression.<xref ref-type="bibr" rid="article-17687.r9">[9]</xref></p>
          </list-item>
        </list>
        <p>
<bold>SNRI</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Serotonin and norepinephrine reuptake inhibitors (SNRIs) block serotonin&#x000a0;and norepinephrine reuptake in the synapse, increasing postsynaptic receptors' stimulation. SNRIs differ in their affinity for the serotonin and norepinephrine transporter.</p>
          </list-item>
          <list-item>
            <p>In contrast with other selective serotonin-norepinephrine reuptake inhibitors like duloxetine, venlafaxine, and desvenlafaxine; milnacipran and levomilnacipran&#x000a0;has higher selectivity for inhibiting norepinephrine reuptake than serotonin reuptake<xref ref-type="bibr" rid="article-17687.r10">[10]</xref><xref ref-type="bibr" rid="article-17687.r11">[11]</xref></p>
          </list-item>
        </list>
        <p>
<bold>Atypical Antidepressants</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Atypical antidepressants<bold>&#x000a0;</bold>have<bold>&#x000a0;</bold>various mechanisms of action.</p>
          </list-item>
          <list-item>
            <p>Bupropion, for example, works by inhibiting the reuptake of dopamine and norepinephrine at the presynaptic cleft.<xref ref-type="bibr" rid="article-17687.r12">[12]</xref></p>
          </list-item>
          <list-item>
            <p>Agomelatine works as an agonist at melatonin receptors MT1 and MT2. It also antagonizes serotonergic 5-HT2C receptors, promoting dopamine and norepinephrine release.<xref ref-type="bibr" rid="article-17687.r13">[13]</xref>&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Mirtazapine works by blocking alpha-2 adrenergic receptors on the cell bodies and nerve terminals, promoting the release of norepinephrine into the synapse. Furthermore, mirtazapine antagonizes the 5-HT receptor, which has been shown to increase norepinephrine and dopamine in the brain's cortical regions.<xref ref-type="bibr" rid="article-17687.r7">[7]</xref></p>
          </list-item>
        </list>
        <p>
<bold> Serotonin Modulators</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Serotonin modulators such as vilazodone inhibit the presynaptic reuptake of serotonin. It is also a partial agonist at the postsynaptic serotonin 5-HT1A receptor.&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Trazodone acts upon postsynaptic serotonin 5-HT2A and 5-HT2C receptors and weakly inhibits presynaptic serotonin reuptake. In addition, Trazodone&#x000a0;has additional&#x000a0;postsynaptic alpha-adrenergic receptors and histamine receptors blocking activity.</p>
          </list-item>
          <list-item>
            <p>Nefazodone antagonizes postsynaptic serotonin 5-HT2A receptors and inhibits&#x000a0;presynaptic serotonin and norepinephrine reuptake; these actions increase&#x000a0;serotonergic transmission at&#x000a0;5-HT1A receptors.<xref ref-type="bibr" rid="article-17687.r12">[12]</xref></p>
          </list-item>
        </list>
        <p>
<bold>Tricyclic Antidepressants</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>TCA,<bold>&#x000a0;</bold>like amitriptyline, inhibits the reuptake of norepinephrine and serotonin at the presynaptic neuronal membrane. Amitriptyline also has an affinity for muscarinic M1 receptors and histamine H1 receptors. TCA thus&#x000a0;can cause sedation and anticholinergic side effects.<xref ref-type="bibr" rid="article-17687.r14">[14]</xref></p>
          </list-item>
        </list>
        <p>
<bold>Monoamine Oxidase Inhibitors</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>&#x000a0;MAOIs inhibit the monoamine oxidase enzyme responsible for catabolizing serotonin, norepinephrine, and dopamine. Monoamine oxidase inhibitors were the first antidepressants discovered. MAOIs are not recognized as the first-line treatment for depression because of the&#x000a0;adverse effects and drug-drug interactions.<xref ref-type="bibr" rid="article-17687.r15">[15]</xref>&#x000a0;</p>
          </list-item>
        </list>
        <p>
<bold>NMDA Antagonists</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Dysregulation in glutamatergic neurotransmission is implied&#x000a0;in the&#x000a0;pathophysiology of depression. In clinical research of depression, alteration of glutamate and gamma-aminobutyric acid (GABA) activity have been recognized. Glutamate is an excitatory neurotransmitter that binds to NMDA(N-methyl-D-aspartate receptors). Consequently, NMDA antagonists are useful in the treatment of depression.</p>
          </list-item>
          <list-item>
            <p>Esketamine- Esketamine, the S-enantiomer of racemic ketamine, is a non-selective, non-competitive N-methyl-D-aspartate (NMDA) antagonist. It is indicated in treatment-resistant depression.<xref ref-type="bibr" rid="article-17687.r16">[16]</xref></p>
          </list-item>
          <list-item>
            <p>Dextromethorphan is an uncompetitive&#x000a0;NMDA receptor antagonist&#x000a0;and opioid &#x003c3;&#x000a0;receptor agonist. Bupropion, as discussed above, works by inhibiting the uptake of dopamine and norepinephrine. The fixed drug combination of dextromethorphan-bupropion has a rapid onset of action(approximately one week) in patients with major depressive disorder.<xref ref-type="bibr" rid="article-17687.r3">[3]</xref><xref ref-type="bibr" rid="article-17687.r17">[17]</xref></p>
          </list-item>
        </list>
        <p>
<bold>BDNF Hypothesis</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>The initial increase in synaptic serotonin eventually leads to increased neuroprotective proteins such as brain-derived neurotrophic factor (BDNF). BDNF concentrations in depression normalize in response to pharmacological treatment. An increase in BDNF level&#x000a0;and enhanced neuroplasticity leads to the remission of depression.<xref ref-type="bibr" rid="article-17687.r18">[18]</xref></p>
          </list-item>
        </list>
      </sec>
      <sec id="article-17687.s4" sec-type="Administration">
        <title>Administration</title>
        <p>Commercially available antidepressants are currently available for administration in various dosage forms, including oral tablets, oral extended-release tablets, oral suspensions, topical creams, and transdermal patches. Studies examine alternative administration routes via inhalation, intranasal, sublingual, and rectal forms, and success was obtained in intranasal esketamine.<xref ref-type="bibr" rid="article-17687.r19">[19]</xref>&#x000a0;According to the manufacturer's prescribing information, the usual starting and maintenance doses of commonly used antidepressants appear below. Total daily oral doses may need to be given as two or three equally divided doses per day, depending on antidepressants and comorbidities.&#x000a0;</p>
        <p>
<bold>SSRIs</bold>
</p>
        <p>Citalopram</p>
        <list list-type="bullet">
          <list-item>
            <p>The starting dose is 20 mg daily, and the usual maintenance dose is 20 to 40 mg daily.</p>
          </list-item>
        </list>
        <p>Escitalopram</p>
        <list list-type="bullet">
          <list-item>
            <p>The starting dose is 5-10 mg daily, and the usual maintenance dose is 10 to 20 mg daily.</p>
          </list-item>
        </list>
        <p>Paroxetine</p>
        <list list-type="bullet">
          <list-item>
            <p>The starting dose is 20 mg daily, and the usual maintenance dose is 20 to 40 mg daily.</p>
          </list-item>
        </list>
        <p>Sertraline</p>
        <list list-type="bullet">
          <list-item>
            <p>The starting dose is 50 mg daily, and the usual maintenance dose is 100 to 200 mg daily.</p>
          </list-item>
        </list>
        <p>Fluoxetine</p>
        <list list-type="bullet">
          <list-item>
            <p>The starting dose is 20 mg daily, and the usual maintenance dose is 20 to 60 mg daily.</p>
          </list-item>
        </list>
        <p>Fluvoxamine</p>
        <list list-type="bullet">
          <list-item>
            <p>The starting dose is 50 mg daily, and the usual maintenance dose is 50 to 200 mg daily.</p>
          </list-item>
        </list>
        <p>&#x000a0;<bold>SNRIs</bold></p>
        <p>&#x000a0;Venlafaxine</p>
        <list list-type="bullet">
          <list-item>
            <p>The starting dose is 75 mg daily, and the usual maintenance dose is 225 to 375 mg daily.</p>
          </list-item>
        </list>
        <p>Desvenlafaxine</p>
        <list list-type="bullet">
          <list-item>
            <p>The starting dose is 25 to 50 mg daily; the usual maintenance dose is 50 mg daily.</p>
          </list-item>
        </list>
        <p>Duloxetine&#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0;</p>
        <list list-type="bullet">
          <list-item>
            <p>The starting dose is 30 mg daily, and the usual maintenance dose is 60 mg daily.</p>
          </list-item>
        </list>
        <p>Milnacipran</p>
        <list list-type="bullet">
          <list-item>
            <p>The starting dose is 12.5 mg daily, and the usual maintenance dose is 100 mg daily.</p>
          </list-item>
        </list>
        <p>Levomilnacipran</p>
        <list list-type="bullet">
          <list-item>
            <p>The starting dose is 20 mg daily, and the usual maintenance dose is 40 to 120 mg daily.</p>
          </list-item>
        </list>
        <p>
<bold>Atypical Antidepressants</bold>
</p>
        <p>Bupropion</p>
        <list list-type="bullet">
          <list-item>
            <p>The starting dose is&#x000a0;150 mg daily, and the usual maintenance dose is 300 mg daily.</p>
          </list-item>
        </list>
        <p>Mirtazapine</p>
        <list list-type="bullet">
          <list-item>
            <p>The starting dose is 15 mg daily, and the usual maintenance dose is 15 to 45 mg daily.&#x000a0;</p>
          </list-item>
        </list>
        <p>
<bold>Serotonin Modulators</bold>
</p>
        <p>Nefazodone</p>
        <list list-type="bullet">
          <list-item>
            <p>The starting dose is&#x000a0;200&#x000a0;mg daily, and the usual maintenance dose is 200 to 600 mg daily.</p>
          </list-item>
        </list>
        <p>Trazodone</p>
        <list list-type="bullet">
          <list-item>
            <p>The starting dose is 150 mg daily, and the usual maintenance dose is 200 to 400 mg daily.&#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0;</p>
          </list-item>
        </list>
        <p>Vortioxetine</p>
        <list list-type="bullet">
          <list-item>
            <p>The starting dose is 10 mg daily, and the usual maintenance dose is 20 mg daily.</p>
          </list-item>
        </list>
        <p>
<bold>Tricyclic Antidepressants (TCAs)</bold>
</p>
        <p>Amitriptyline</p>
        <list list-type="bullet">
          <list-item>
            <p>The starting dose is 50 mg daily, and the usual maintenance dose is 100 to 200 mg daily.</p>
          </list-item>
        </list>
        <p>Nortriptyline</p>
        <list list-type="bullet">
          <list-item>
            <p>The starting dose is 25 mg daily, and the usual maintenance dose is 50 to 150 mg daily.&#x000a0;</p>
          </list-item>
        </list>
        <p>Imipramine</p>
        <list list-type="bullet">
          <list-item>
            <p>The starting dose is 75 mg daily, and the usual maintenance dose is 150 mg daily.</p>
          </list-item>
        </list>
        <p>Clomipramine(off-label use)</p>
        <list list-type="bullet">
          <list-item>
            <p>The starting dose is 25 mg daily, and the usual maintenance dose is 100 to 250 mg daily.</p>
          </list-item>
        </list>
        <p>Desipramine</p>
        <list list-type="bullet">
          <list-item>
            <p>The starting dose is 100 mg daily, and the usual maintenance dose is 100 to 300 mg daily.</p>
          </list-item>
        </list>
        <p>
<bold>Monoamine Oxidase Inhibitors (MAOIs)</bold>
</p>
        <p>Isocarboxazid</p>
        <list list-type="bullet">
          <list-item>
            <p>The starting dose is&#x000a0;20 mg daily, and the usual maintenance dose is 20 to 60 mg daily.&#x000a0; &#x000a0; &#x000a0;</p>
          </list-item>
        </list>
        <p>Phenelzine</p>
        <list list-type="bullet">
          <list-item>
            <p>The starting dose is&#x000a0;45 mg daily, and the usual maintenance dose is 60 to 90 mg daily.</p>
          </list-item>
        </list>
        <p>Selegiline transdermal patch</p>
        <list list-type="bullet">
          <list-item>
            <p>The starting dose is 6 mg/24 hours; the usual maintenance dose is 6 to 12 mg/24 hours.</p>
          </list-item>
        </list>
        <p>
<bold>NMDA antagonists</bold>
</p>
        <p>Esketamine (nasal spray)</p>
        <list list-type="bullet">
          <list-item>
            <p>The induction phase(week 1 to 4) dose is 56 mg/84 mg twice weekly, maintenance phase(week 5 to 8) dose is 56 mg/84 mg once a week.&#x000a0;Dosing should be&#x000a0;individualized(&#x000a0;least frequent dosing)&#x000a0;according to the clinical response.</p>
          </list-item>
        </list>
        <p>Dextromethorphan/bupropion(extended-release tablets)</p>
        <list list-type="bullet">
          <list-item>
            <p>The starting dose is 45 mg dextromethorphan/105 mg&#x000a0;bupropion once daily in the morning. After three days,&#x000a0;increase the dose to the maximum recommended dosage of one tablet twice daily,&#x000a0;separated&#x000a0;by at least 8 hours. It is not recommended to exceed two doses within the same day.<xref ref-type="bibr" rid="article-17687.r3">[3]</xref></p>
          </list-item>
        </list>
        <p>
<bold>Switching Antidepressants</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>A washout period of 2&#x02013;5 half-lives (most frequently 2&#x02013;5 days) between cessation of the previous drug and the introduction of a new drug is the safest switching strategy from the point of view of drug interactions.<xref ref-type="bibr" rid="article-17687.r20">[20]</xref></p>
          </list-item>
        </list>
        <p>
<bold>Treatment-Resistant Depression</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>According to the FDA and EMA, patients are considered to have treatment-resistant depression (TRD) when their major depressive disorder fails to respond sufficiently to &#x02265;2 consecutive antidepressants in a single episode.<xref ref-type="bibr" rid="article-17687.r21">[21]</xref>&#x000a0;Treatment-resistant depression requires augmentation with another antidepressant or atypical antipsychotic agent.&#x000a0;</p>
          </list-item>
        </list>
        <p>
<bold>Psychotherapy</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>The combination of pharmacotherapy and psychotherapy is more effective than pharmacotherapy alone.<xref ref-type="bibr" rid="article-17687.r22">[22]</xref></p>
          </list-item>
        </list>
      </sec>
      <sec id="article-17687.s5" sec-type="Adverse Effects">
        <title>Adverse Effects</title>
        <p>The most prevalent side effects of antidepressants include sexual dysfunction, drowsiness, weight gain, insomnia, anxiety, dizziness, headache, dry mouth, blurred vision, nausea, rash, and tremor. Patients may also describe asthenia and malaise while on antidepressant therapy. Clinicians may note symptoms of hyperprolactinemia, syndrome of inappropriate antidiuretic hormone (SIADH), and hyponatremia in patients taking antidepressants.<xref ref-type="bibr" rid="article-17687.r23">[23]</xref></p>
        <p>
<bold>SSRI</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Sexual dysfunction</p>
          </list-item>
          <list-item>
            <p>Headache</p>
          </list-item>
          <list-item>
            <p>QTc prolongation<xref ref-type="bibr" rid="article-17687.r24">[24]</xref></p>
          </list-item>
        </list>
        <p>&#x000a0;<bold>SNRI</bold></p>
        <list list-type="bullet">
          <list-item>
            <p>Hypertension</p>
          </list-item>
          <list-item>
            <p>Headache</p>
          </list-item>
          <list-item>
            <p>Diaphoresis</p>
          </list-item>
          <list-item>
            <p>Bone resorption<xref ref-type="bibr" rid="article-17687.r25">[25]</xref></p>
          </list-item>
        </list>
        <p>&#x000a0;<bold>Atypical Antidepressants</bold></p>
        <list list-type="bullet">
          <list-item>
            <p>Agomelatine- hepatotoxicity</p>
          </list-item>
          <list-item>
            <p>Mirtazapine-Sedation, Weight gain<xref ref-type="bibr" rid="article-17687.r26">[26]</xref></p>
          </list-item>
          <list-item>
            <p>Bupropion- Seizures<xref ref-type="bibr" rid="article-17687.r27">[27]</xref></p>
          </list-item>
        </list>
        <p>&#x000a0;<bold>Serotonin Modulators</bold></p>
        <list list-type="bullet">
          <list-item>
            <p>Nefazodone- Hepatotoxicity(&#x000a0;acute hepatitis with cholestasis and variable degrees of centrilobular necrosis)<xref ref-type="bibr" rid="article-17687.r28">[28]</xref></p>
          </list-item>
          <list-item>
            <p>Vilazodone- Diarrhea</p>
          </list-item>
          <list-item>
            <p>Vortioxetine- Nausea&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Trazodone- Sedation, Priapism<xref ref-type="bibr" rid="article-17687.r29">[29]</xref><xref ref-type="bibr" rid="article-17687.r30">[30]</xref></p>
          </list-item>
        </list>
        <p>
<bold>Tricyclic Antidepressants</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Dry mouth</p>
          </list-item>
          <list-item>
            <p>Urinary Retention</p>
          </list-item>
          <list-item>
            <p>Constipation</p>
          </list-item>
          <list-item>
            <p>QRS prolongation</p>
          </list-item>
          <list-item>
            <p>Seizures</p>
          </list-item>
          <list-item>
            <p>Orthostatic Hypotension<xref ref-type="bibr" rid="article-17687.r31">[31]</xref></p>
          </list-item>
        </list>
        <p>&#x000a0;<bold>MAO Inhibitors</bold></p>
        <list list-type="bullet">
          <list-item>
            <p>Potential for serotonin syndrome<xref ref-type="bibr" rid="article-17687.r32">[32]</xref></p>
          </list-item>
          <list-item>
            <p>Sexual dysfunction</p>
          </list-item>
        </list>
        <p>&#x000a0;<bold>Esketamine</bold></p>
        <list list-type="bullet">
          <list-item>
            <p>Significant potential for misuse.&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Dissociative or perceptual changes and sedation<xref ref-type="bibr" rid="article-17687.r33">[33]</xref></p>
          </list-item>
        </list>
        <p>
<bold>Dextromethorphan/Bupropion</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Dizziness, headache, somnolence, and dry mouth<xref ref-type="bibr" rid="article-17687.r3">[3]</xref></p>
          </list-item>
        </list>
        <p>
<bold>US Boxed Warning(FDA)</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Suicidal thoughts and behaviors:&#x000a0;Antidepressants increased the risk of suicidal thoughts and behavior in pediatric and young adult patients. Closely monitor all antidepressant-treated patients for clinical worsening and the emergence of suicidal thoughts and behaviors.<xref ref-type="bibr" rid="article-17687.r34">[34]</xref></p>
          </list-item>
        </list>
      </sec>
      <sec id="article-17687.s6" sec-type="Contraindications">
        <title>Contraindications</title>
        <list list-type="bullet">
          <list-item>
            <p>There are several scenarios where antidepressant use may be contraindicated. These scenarios vary between and within classes.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Antidepressants should be used cautiously in patients with known hypersensitivities or taking other psychotropic medications.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs), for example, should not be taken with other SSRIs, monoamine oxidase inhibitors, tricyclic antidepressants, and other psychotropics; this is due to the risk of serotonin syndrome, which can lead to severe neuromuscular and autonomic symptoms.<xref ref-type="bibr" rid="article-17687.r35">[35]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Tricyclic antidepressants can provide another good example of relative contraindications in antidepressant therapy. Clinicians should be mindful when prescribing tricyclic antidepressants to individuals with cardiovascular disease. Tricyclic antidepressants have been shown to cause orthostatic hypotension. Additionally, tricyclic antidepressants may lead to heart block in patients with preexisting bundle-branch disease.<xref ref-type="bibr" rid="article-17687.r36">[36]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Buproprion, an atypical antidepressant, has seizure disorder listed as a major contraindication. This contraindication applies to patients with an active seizure diagnosis or prior seizure activity history. Like other antidepressants, bupropion should not be used in patients taking monoamine oxidase inhibitors or drugs that can lower the seizure threshold.<xref ref-type="bibr" rid="article-17687.r37">[37]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Liver injury due to previous treatment is a contraindication to nefazodone therapy.<xref ref-type="bibr" rid="article-17687.r28">[28]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Esketamine is contraindicated in aneurysmal vascular disease(thoracic and abdominal aorta, intracranial, and peripheral arterial vessels) and arteriovenous malformations, according to the product labeling.</p>
          </list-item>
          <list-item>
            <p>Dextromethorphan/Bupropion is contraindicated in patients with a seizure disorder, bulimia/anorexia nervosa, and concomitant Use with&#x000a0;MAO inhibitors or within 14 days of stopping treatment with dextromethorphan/bupropion.<xref ref-type="bibr" rid="article-17687.r38">[38]</xref><xref ref-type="bibr" rid="article-17687.r39">[39]</xref><xref ref-type="bibr" rid="article-17687.r40">[40]</xref></p>
          </list-item>
        </list>
      </sec>
      <sec id="article-17687.s7" sec-type="Monitoring">
        <title>Monitoring</title>
        <p>
<bold>Therapeutic Drug Monitoring</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Clinicians may find utility in monitoring antidepressant levels in their patients. This therapeutic drug monitoring strategy is based on serum or plasma concentrations of antidepressants, which researchers believe is a more reliable index than dosage. Therapeutic drug monitoring of antidepressants is beneficial with agents that have a reliable therapeutic range established.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Nonetheless, it may also be helpful in patients who are refractory to treatment, have adverse effects, or have a history of noncompliance. Therapeutic drug monitoring is expensive, so clinicians must weigh the benefits to the cost of the study.<xref ref-type="bibr" rid="article-17687.r37">[37]</xref></p>
          </list-item>
        </list>
        <p><bold>Psychiatric Assessment</bold>&#x000a0;</p>
        <list list-type="bullet">
          <list-item>
            <p>Various scales in clinical practice can assist in trending a patient&#x02019;s symptoms to determine therapeutic response.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Patient Health Questionnaire (PHQ-9).<xref ref-type="bibr" rid="article-17687.r41">[41]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Hamilton Rating Scale for Depression(HDRS-17)&#x000a0;</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Montgomery-Asberg Depression Rating Scale(MADRS)<xref ref-type="bibr" rid="article-17687.r42">[42]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>In addition, monitoring for suicidal ideation is of paramount importance.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Clinicians should monitor for adverse drug reactions, coexisting anxiety, or medical disorders at each visit.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Clinicians&#x000a0;should also assess the response to therapy and consider augmenting or switching antidepressants in an inadequate response.</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-17687.s8" sec-type="Toxicity">
        <title>Toxicity</title>
        <list list-type="bullet">
          <list-item>
            <p>The toxicity of antidepressants varies greatly not only between classes but within them as well. Antidepressants are frequently used to self-poison in an attempt to commit suicide, particularly in women. Older tricyclic antidepressants (TCAs) are more toxic than newer antidepressant classes. Such as selective serotonin reuptake inhibitors (SSRIs). Researchers can track drug toxicity using the fatal toxicity index, a ratio of self-poisoning mortality rates to prescription rates. Researchers may also employ a case fatality index, which compares fatal versus non-fatal self-poisoning attempts. With that said, clinicians may wish to alter treatment strategies depending on a patient&#x02019;s suicide risk.<xref ref-type="bibr" rid="article-17687.r43">[43]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>According to the literature review,&#x000a0;toxicity is higher for TCAs and&#x000a0;MAO inhibitors followed by venlafaxine, bupropion, and mirtazapine and is lower for SSRIs. Among the selective serotonin reuptake inhibitors, citalopram and fluvoxamine appear to be associated with higher case fatality rates in overdose.<xref ref-type="bibr" rid="article-17687.r44">[44]</xref></p>
          </list-item>
        </list>
        <p>
<bold>SSRI Poisoning</bold>
</p>
        <p>
<bold>Clinical Features</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>CNS- drowsiness, tremor</p>
          </list-item>
          <list-item>
            <p>CVS- QRS and QTc interval prolongation(especially with citalopram and escitalopram)</p>
          </list-item>
          <list-item>
            <p>Potential serotonin syndrome: hyperthermia, hypertonia, hyperreflexia, clonus.</p>
          </list-item>
        </list>
        <p>
<bold>Management</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Secure airway, breathing, and circulation; intubate as clinically indicated.</p>
          </list-item>
          <list-item>
            <p>Treat prolonged QRS intervals with sodium bicarbonate</p>
          </list-item>
          <list-item>
            <p>Prolonged QTc leading to torsades- Administer magnesium sulfate 2 g IV.</p>
          </list-item>
          <list-item>
            <p>Treat seizures with benzodiazepines (e.g., lorazepam 1 to 2 mg IV) as needed.</p>
          </list-item>
          <list-item>
            <p>SSRIs are relatively safe, although serotonin syndrome&#x000a0;is common in overdose. The exception&#x000a0;is citalopram, which&#x000a0;is significantly associated with QTc prolongation.<xref ref-type="bibr" rid="article-17687.r45">[45]</xref></p>
          </list-item>
        </list>
        <p>
<bold>SNRI Poisoning</bold>
</p>
        <p>
<bold>Clinical Features</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Tachycardia</p>
          </list-item>
          <list-item>
            <p>Hypertension</p>
          </list-item>
          <list-item>
            <p>Electrocardiogram changes (e.g., prolongation of QT interval, bundle branch block, QRS prolongation), ventricular tachycardia</p>
          </list-item>
          <list-item>
            <p>Changes in the level of consciousness (ranging from somnolence to coma)</p>
          </list-item>
          <list-item>
            <p>Mydriasis</p>
          </list-item>
          <list-item>
            <p>Serotonin syndrome</p>
          </list-item>
          <list-item>
            <p>Rhabdomyolysis</p>
          </list-item>
          <list-item>
            <p>Liver necrosis</p>
          </list-item>
          <list-item>
            <p>Death&#x000a0;&#x000a0;</p>
          </list-item>
        </list>
        <p>
<bold>Management </bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>In case of acute overdose with SNRI, the clinician should ensure an adequate airway, breathing, and circulation.</p>
          </list-item>
          <list-item>
            <p>For serotonin syndrome, specific treatment (such as with cyproheptadine may be considered)</p>
          </list-item>
          <list-item>
            <p>Treat prolonged QRS intervals with sodium bicarbonate</p>
          </list-item>
          <list-item>
            <p>Prolonged QTc leading to torsades- Administer magnesium sulfate 2 g IV.</p>
          </list-item>
          <list-item>
            <p>Consider&#x000a0;extracorporeal life support in severe poisoning with venlafaxine.<xref ref-type="bibr" rid="article-17687.r46">[46]</xref></p>
          </list-item>
        </list>
        <p>
<bold>Atypical Antidepressants Poisoning</bold>
</p>
        <p>
<bold>Bupropion</bold>
</p>
        <p>
<bold>Clinical features</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Tachycardia</p>
          </list-item>
          <list-item>
            <p>Hypertension</p>
          </list-item>
          <list-item>
            <p>Seizures<xref ref-type="bibr" rid="article-17687.r47">[47]</xref></p>
          </list-item>
        </list>
        <p>
<bold>Management</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Ensure an adequate airway, oxygenation, and ventilation.</p>
          </list-item>
          <list-item>
            <p>EEG monitoring is recommended for the first 48&#x000a0;hours post-ingestion.</p>
          </list-item>
          <list-item>
            <p>Administer intravenous benzodiazepine for seizures.<xref ref-type="bibr" rid="article-17687.r48">[48]</xref><xref ref-type="bibr" rid="article-17687.r49">[49]</xref></p>
          </list-item>
        </list>
        <p>
<bold>Mirtazapine</bold>
</p>
        <p>
<bold>Clinical Features</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Disorientation</p>
          </list-item>
          <list-item>
            <p>Drowsiness</p>
          </list-item>
          <list-item>
            <p>Impaired memory</p>
          </list-item>
          <list-item>
            <p>Bradyarrhythmias<xref ref-type="bibr" rid="article-17687.r50">[50]</xref></p>
          </list-item>
        </list>
        <p>
<bold>Management</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Ensure an adequate airway, oxygenation, and ventilation</p>
          </list-item>
          <list-item>
            <p>Monitor cardiac rhythm and vital signs.</p>
          </list-item>
          <list-item>
            <p>Treat arrhythmias according to ACLS and PALS protocol.&#x000a0;</p>
          </list-item>
        </list>
        <p>
<bold>Serotonin Modulators Poisoning</bold>
</p>
        <p>
<bold>Trazodone</bold>
</p>
        <p>
<bold>Clinical Features</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Arrhythmias</p>
          </list-item>
          <list-item>
            <p>Respiratory arrest</p>
          </list-item>
          <list-item>
            <p>Coma</p>
          </list-item>
          <list-item>
            <p>Priapism<xref ref-type="bibr" rid="article-17687.r51">[51]</xref></p>
          </list-item>
        </list>
        <p>
<bold>Management</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Treatment should be symptomatic and supportive in the case of hypotension or excessive sedation.</p>
          </list-item>
          <list-item>
            <p>Priapism requires urgent evaluation by a urologist.&#x000a0;</p>
          </list-item>
          <list-item>
            <p>In patients with ischemic priapism, intracavernosal injection such as phenylephrine.<xref ref-type="bibr" rid="article-17687.r52">[52]</xref></p>
          </list-item>
        </list>
        <p>
<bold>Vilazodone</bold>
</p>
        <p>
<bold>Clinical Features</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>drowsiness</p>
          </list-item>
          <list-item>
            <p>vomiting</p>
          </list-item>
          <list-item>
            <p>tachycardia</p>
          </list-item>
          <list-item>
            <p>serotonin syndrome(altered mental status, autonomic instability, and neuromuscular abnormalities)<xref ref-type="bibr" rid="article-17687.r53">[53]</xref></p>
          </list-item>
        </list>
        <p>
<bold>Management</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Ensure an adequate airway, breathing, and circulation.&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Serotonin syndrome-&#x000a0;&#x000a0;Vilazodone has up to 30-fold higher potency for serotonin reuptake inhibition than conventional SSRIs.&#x000a0;Consequently, management of serotonin syndrome is the mainstay of therapy.</p>
          </list-item>
          <list-item>
            <p>Treatment&#x000a0;of serotonin syndrome.&#x000a0;
<list list-type="bullet"><list-item><p>Administer&#x000a0;benzodiazepines (e.g., lorazepam 1 to 2 mg IV per dose) till the patient is asymptomatic.&#x000a0;</p></list-item><list-item><p>Administer IV fluids.&#x000a0;</p></list-item><list-item><p>Consider sedation, paralysis, and endotracheal intubation for severe hyperthermia.</p></list-item><list-item><p>Administer antidote&#x000a0;cyproheptadine(antagonist at 5-HT1A and 5-HT2A receptors).<xref ref-type="bibr" rid="article-17687.r54">[54]</xref></p></list-item></list>
</p>
          </list-item>
        </list>
        <p>
<bold>TCAs Poisoning</bold>
</p>
        <p>
<bold>Clinical Features</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Anticholinergic<bold>-&#x000a0;</bold>Dilated pupils, absent bowel sounds, constipation, urinary retention</p>
          </list-item>
          <list-item>
            <p>Cardiac-&#x000a0;Tachycardia, hypotension, conduction abnormalities, QRS duration &#x0003e;100 msec</p>
          </list-item>
          <list-item>
            <p>Neurologic-&#x000a0;Sedation, seizures</p>
          </list-item>
        </list>
        <p>
<bold>Management</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Maintain airway, breathing, circulation</p>
          </list-item>
          <list-item>
            <p>Treat hypotension with intravenous crystalloid. Administer vasopressors such as norepinephrine in refractory hypotension.&#x000a0;</p>
          </list-item>
          <list-item>
            <p>If QRS &#x0003e;100 msec, administer IV sodium bicarbonate.</p>
          </list-item>
          <list-item>
            <p>Administer activated charcoal(1g/kg) if the patient presents within 2 hours of ingestion; often, charcoal is avoided due to the&#x000a0;presence&#x000a0;of ileus.</p>
          </list-item>
          <list-item>
            <p>Administer benzodiazepines (lorazepam 2 mg IV) for seizures.&#x000a0;</p>
          </list-item>
          <list-item>
            <p>QRS interval longer than 100 ms is a reliable predictor of serious complications.<xref ref-type="bibr" rid="article-17687.r55">[55]</xref></p>
          </list-item>
        </list>
        <p>
<bold>MAOI Poisoning</bold>
</p>
        <p>
<bold>Clinical Features</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Serotonin syndrome</p>
          </list-item>
          <list-item>
            <p>Hypertensive crisis</p>
          </list-item>
        </list>
        <p>
<bold>Management</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Establish adequate airway, breathing, and circulation.</p>
          </list-item>
          <list-item>
            <p>Administer parenteral agents for hypertensive crisis.</p>
          </list-item>
          <list-item>
            <p>Serotonin syndrome- Administer IV fluids, benzodiazepines, and cyproheptadine.<xref ref-type="bibr" rid="article-17687.r56">[56]</xref></p>
          </list-item>
        </list>
        <p>
<bold>NMDA antagonist (esketamine) Poisoning</bold>
</p>
        <p>
<bold>Clinical Features</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Sedation</p>
          </list-item>
          <list-item>
            <p>Dissociation</p>
          </list-item>
          <list-item>
            <p>Ulcerative or Interstitial Cystitis</p>
          </list-item>
          <list-item>
            <p>Embryo-fetal Toxicity</p>
          </list-item>
        </list>
        <p>
<bold>Management</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Establish adequate airway, breathing, and circulation.</p>
          </list-item>
          <list-item>
            <p>There is no specific antidote for esketamine overdose. In the case of overdose, clinicians should consider the possibility of multiple drug involvement. Contact a certified poison control center for the most up-to-date information on managing overdosage.</p>
          </list-item>
        </list>
        <p>
<bold>Dextromethorphan/bupropion poisoning</bold>
</p>
        <p>
<bold>Clinical Features</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Seizures</p>
          </list-item>
          <list-item>
            <p>Serotonin Syndrome</p>
          </list-item>
          <list-item>
            <p>Psychosis<xref ref-type="bibr" rid="article-17687.r57">[57]</xref></p>
          </list-item>
        </list>
        <p>
<bold>Management</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Ensure an adequate airway, oxygenation, and ventilation.</p>
          </list-item>
          <list-item>
            <p>There is no specific antidote. Provide supportive care.</p>
          </list-item>
          <list-item>
            <p>Administer benzodiazepines for seizures.<xref ref-type="bibr" rid="article-17687.r49">[49]</xref></p>
          </list-item>
          <list-item>
            <p>Consult a medical toxicologist or a certified poison control center.<xref ref-type="bibr" rid="article-17687.r58">[58]</xref></p>
          </list-item>
        </list>
      </sec>
      <sec id="article-17687.s9" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>While antidepressants are beneficial in treating depression and its other indications, many patients fail to receive adequate treatment. To effectively manage depression, a clinician must employ an interprofessional team-centered approach to effectively detect and diagnose the depression, provide patient education, use evidence-based pharmacotherapy, provide close-follow up for compliance, identify side effects, and determine treatment effectiveness.<xref ref-type="bibr" rid="article-17687.r59">[59]</xref>&#x000a0;Studies show multiple factors contribute to patient compliance with antidepressant medications. Generally, concerns about drug side effects were predictive of adherence.<xref ref-type="bibr" rid="article-17687.r60">[60]</xref>&#x000a0;</p>
        <p>Patient comorbidities can also contribute to compliance with antidepressant medications. Particularly, conditions that impact one&#x02019;s cognitive status can lead to non-compliance.<xref ref-type="bibr" rid="article-17687.r61">[61]</xref>&#x000a0;Alcohol or substance abuse, cardiovascular disease, metabolic disorders, young age, low-income residents, and old-generation antidepressant medication usage were predictive of lower adherence, particularly in the acute phase.<xref ref-type="bibr" rid="article-17687.r62">[62]</xref></p>
        <p>Identifying and addressing these concerns is pivotal in the management of depression and the prescription of antidepressant medications. Several randomized controlled trials support the collaborative care approach in treating depression. Suggestions are that the program includes a depression care manager, psychiatric consultant, prescribing physician, and the patient. The depression care manager will manage the antidepressants, provide education, and coordinate referrals if necessary. The psychiatric consultant will be responsible for improving treatment strategies in patients who are not meeting expectations.<xref ref-type="bibr" rid="article-17687.r63">[63]</xref>&#x000a0;Patients may be receiving more than one antidepressant medication at a time. Hence it is essential to identify all the drugs involved in poisoning for the emergency physicians and triage nurses.</p>
        <p>Other healthcare team members who must contribute to antidepressant care include the pharmacist and the nursing staff. Psychiatric specialty nurses are best equipped to recognize treatment failure, counsel patients on the medication, monitor adverse events, and assess compliance. Pharmacists can verify agent selection and dosing and perform medication reconciliation for drug interactions. Both pharmacists and nurses need open access to the prescriber in case of concern.</p>
        <p>In overdose of antidepressants, emergency department physicians should rapidly stabilize the patient ensuring adequate airway, breathing, and circulation. Cardiac arrhythmias, serotonin syndrome, and seizures require ICU care under the supervision of a critical care physician. Medical toxicologists should be consulted for severe poisoning. Deliberate overdose requires consultation with a psychiatrist. As illustrated above, clinicians (MDs, DOs, NPs, PAs), specialists, pharmacists, nurses, and other healthcare providers are involved in taking care of the patient receiving antidepressant therapy. All interprofessional team members functioning as one unit&#x000a0;can&#x000a0;maximize efficacy and minimize adverse reactions, translating&#x000a0;to optimal patient outcomes. [Level 5]</p>
      </sec>
      <sec id="article-17687.s10">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=17687&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=17687">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/17687/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=17687">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-17687.s11">
        <title>References</title>
        <ref id="article-17687.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Guti&#x000e9;rrez-Rojas</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Porras-Segovia</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Dunne</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Andrade-Gonz&#x000e1;lez</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Cervilla</surname>
                <given-names>JA</given-names>
              </name>
            </person-group>
            <article-title>Prevalence and correlates of major depressive disorder: a systematic review.</article-title>
            <source>Braz J Psychiatry</source>
            <year>2020</year>
            <season>Nov-Dec</season>
            <volume>42</volume>
            <issue>6</issue>
            <fpage>657</fpage>
            <page-range>657-672</page-range>
            <pub-id pub-id-type="pmid">32756809</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17687.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Fu</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>Ionescu</surname>
                <given-names>DF</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Lane</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Lim</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Sanacora</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Hough</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Manji</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Drevets</surname>
                <given-names>WC</given-names>
              </name>
              <name>
                <surname>Canuso</surname>
                <given-names>CM</given-names>
              </name>
            </person-group>
            <article-title>Esketamine Nasal Spray for Rapid Reduction of Major Depressive Disorder Symptoms in Patients Who Have Active Suicidal Ideation With Intent: Double-Blind, Randomized Study (ASPIRE I).</article-title>
            <source>J Clin Psychiatry</source>
            <year>2020</year>
            <month>May</month>
            <day>12</day>
            <volume>81</volume>
            <issue>3</issue>
            <pub-id pub-id-type="pmid">32412700</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17687.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Iosifescu</surname>
                <given-names>DV</given-names>
              </name>
              <name>
                <surname>Jones</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>O'Gorman</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Streicher</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Feliz</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Fava</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Tabuteau</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>Efficacy and Safety of AXS-05 (Dextromethorphan-Bupropion) in Patients With Major Depressive Disorder: A Phase 3 Randomized Clinical Trial (GEMINI).</article-title>
            <source>J Clin Psychiatry</source>
            <year>2022</year>
            <month>May</month>
            <day>30</day>
            <volume>83</volume>
            <issue>4</issue>
            <pub-id pub-id-type="pmid">35649167</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17687.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cipriani</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Furukawa</surname>
                <given-names>TA</given-names>
              </name>
              <name>
                <surname>Salanti</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Geddes</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>Higgins</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Churchill</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Watanabe</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Nakagawa</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Omori</surname>
                <given-names>IM</given-names>
              </name>
              <name>
                <surname>McGuire</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Tansella</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Barbui</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis.</article-title>
            <source>Lancet</source>
            <year>2009</year>
            <month>Feb</month>
            <day>28</day>
            <volume>373</volume>
            <issue>9665</issue>
            <fpage>746</fpage>
            <page-range>746-58</page-range>
            <pub-id pub-id-type="pmid">19185342</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17687.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Schatzberg</surname>
                <given-names>AF</given-names>
              </name>
            </person-group>
            <article-title>New indications for antidepressants.</article-title>
            <source>J Clin Psychiatry</source>
            <year>2000</year>
            <volume>61 Suppl 11</volume>
            <fpage>9</fpage>
            <page-range>9-17</page-range>
            <pub-id pub-id-type="pmid">10926050</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17687.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wong</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Motulsky</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Abrahamowicz</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Eguale</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Buckeridge</surname>
                <given-names>DL</given-names>
              </name>
              <name>
                <surname>Tamblyn</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Off-label indications for antidepressants in primary care: descriptive study of prescriptions from an indication based electronic prescribing system.</article-title>
            <source>BMJ</source>
            <year>2017</year>
            <month>Feb</month>
            <day>21</day>
            <volume>356</volume>
            <fpage>j603</fpage>
            <pub-id pub-id-type="pmid">28228380</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17687.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Harmer</surname>
                <given-names>CJ</given-names>
              </name>
              <name>
                <surname>Duman</surname>
                <given-names>RS</given-names>
              </name>
              <name>
                <surname>Cowen</surname>
                <given-names>PJ</given-names>
              </name>
            </person-group>
            <article-title>How do antidepressants work? New perspectives for refining future treatment approaches.</article-title>
            <source>Lancet Psychiatry</source>
            <year>2017</year>
            <month>May</month>
            <volume>4</volume>
            <issue>5</issue>
            <fpage>409</fpage>
            <page-range>409-418</page-range>
            <pub-id pub-id-type="pmid">28153641</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17687.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Santarelli</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Saxe</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Gross</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Surget</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Battaglia</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Dulawa</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Weisstaub</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Duman</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Arancio</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Belzung</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Hen</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Requirement of hippocampal neurogenesis for the behavioral effects of antidepressants.</article-title>
            <source>Science</source>
            <year>2003</year>
            <month>Aug</month>
            <day>08</day>
            <volume>301</volume>
            <issue>5634</issue>
            <fpage>805</fpage>
            <page-range>805-9</page-range>
            <pub-id pub-id-type="pmid">12907793</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17687.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sangkuhl</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Klein</surname>
                <given-names>TE</given-names>
              </name>
              <name>
                <surname>Altman</surname>
                <given-names>RB</given-names>
              </name>
            </person-group>
            <article-title>Selective serotonin reuptake inhibitors pathway.</article-title>
            <source>Pharmacogenet Genomics</source>
            <year>2009</year>
            <month>Nov</month>
            <volume>19</volume>
            <issue>11</issue>
            <fpage>907</fpage>
            <page-range>907-9</page-range>
            <pub-id pub-id-type="pmid">19741567</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17687.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lambert</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Bourin</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>SNRIs: mechanism of action and clinical features.</article-title>
            <source>Expert Rev Neurother</source>
            <year>2002</year>
            <month>Nov</month>
            <volume>2</volume>
            <issue>6</issue>
            <fpage>849</fpage>
            <page-range>849-58</page-range>
            <pub-id pub-id-type="pmid">19810918</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17687.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Asnis</surname>
                <given-names>GM</given-names>
              </name>
              <name>
                <surname>Henderson</surname>
                <given-names>MA</given-names>
              </name>
            </person-group>
            <article-title>Levomilnacipran for the treatment of major depressive disorder: a review.</article-title>
            <source>Neuropsychiatr Dis Treat</source>
            <year>2015</year>
            <volume>11</volume>
            <fpage>125</fpage>
            <page-range>125-35</page-range>
            <pub-id pub-id-type="pmid">25657584</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17687.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Horst</surname>
                <given-names>WD</given-names>
              </name>
              <name>
                <surname>Preskorn</surname>
                <given-names>SH</given-names>
              </name>
            </person-group>
            <article-title>Mechanisms of action and clinical characteristics of three atypical antidepressants: venlafaxine, nefazodone, bupropion.</article-title>
            <source>J Affect Disord</source>
            <year>1998</year>
            <month>Dec</month>
            <volume>51</volume>
            <issue>3</issue>
            <fpage>237</fpage>
            <page-range>237-54</page-range>
            <pub-id pub-id-type="pmid">10333980</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17687.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hickie</surname>
                <given-names>IB</given-names>
              </name>
              <name>
                <surname>Rogers</surname>
                <given-names>NL</given-names>
              </name>
            </person-group>
            <article-title>Novel melatonin-based therapies: potential advances in the treatment of major depression.</article-title>
            <source>Lancet</source>
            <year>2011</year>
            <month>Aug</month>
            <day>13</day>
            <volume>378</volume>
            <issue>9791</issue>
            <fpage>621</fpage>
            <page-range>621-31</page-range>
            <pub-id pub-id-type="pmid">21596429</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17687.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gillman</surname>
                <given-names>PK</given-names>
              </name>
            </person-group>
            <article-title>Tricyclic antidepressant pharmacology and therapeutic drug interactions updated.</article-title>
            <source>Br J Pharmacol</source>
            <year>2007</year>
            <month>Jul</month>
            <volume>151</volume>
            <issue>6</issue>
            <fpage>737</fpage>
            <page-range>737-48</page-range>
            <pub-id pub-id-type="pmid">17471183</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17687.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Fiedorowicz</surname>
                <given-names>JG</given-names>
              </name>
              <name>
                <surname>Swartz</surname>
                <given-names>KL</given-names>
              </name>
            </person-group>
            <article-title>The role of monoamine oxidase inhibitors in current psychiatric practice.</article-title>
            <source>J Psychiatr Pract</source>
            <year>2004</year>
            <month>Jul</month>
            <volume>10</volume>
            <issue>4</issue>
            <fpage>239</fpage>
            <page-range>239-48</page-range>
            <pub-id pub-id-type="pmid">15552546</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17687.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Singh</surname>
                <given-names>JB</given-names>
              </name>
              <name>
                <surname>Fedgchin</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Daly</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Xi</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Melman</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>De Bruecker</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Tadic</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Sienaert</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Wiegand</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Manji</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Drevets</surname>
                <given-names>WC</given-names>
              </name>
              <name>
                <surname>Van Nueten</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>Intravenous Esketamine in Adult Treatment-Resistant Depression: A Double-Blind, Double-Randomization, Placebo-Controlled Study.</article-title>
            <source>Biol Psychiatry</source>
            <year>2016</year>
            <month>Sep</month>
            <day>15</day>
            <volume>80</volume>
            <issue>6</issue>
            <fpage>424</fpage>
            <page-range>424-431</page-range>
            <pub-id pub-id-type="pmid">26707087</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17687.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tabuteau</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Jones</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Anderson</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Jacobson</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Iosifescu</surname>
                <given-names>DV</given-names>
              </name>
            </person-group>
            <article-title>Effect of AXS-05 (Dextromethorphan-Bupropion) in Major Depressive Disorder: A Randomized Double-Blind Controlled Trial.</article-title>
            <source>Am J Psychiatry</source>
            <year>2022</year>
            <month>Jul</month>
            <volume>179</volume>
            <issue>7</issue>
            <fpage>490</fpage>
            <page-range>490-499</page-range>
            <pub-id pub-id-type="pmid">35582785</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17687.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Castr&#x000e9;n</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Rantam&#x000e4;ki</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>The role of BDNF and its receptors in depression and antidepressant drug action: Reactivation of developmental plasticity.</article-title>
            <source>Dev Neurobiol</source>
            <year>2010</year>
            <month>Apr</month>
            <volume>70</volume>
            <issue>5</issue>
            <fpage>289</fpage>
            <page-range>289-97</page-range>
            <pub-id pub-id-type="pmid">20186711</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17687.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kaminsky</surname>
                <given-names>BM</given-names>
              </name>
              <name>
                <surname>Bostwick</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>Guthrie</surname>
                <given-names>SK</given-names>
              </name>
            </person-group>
            <article-title>Alternate Routes of Administration of Antidepressant and Antipsychotic Medications.</article-title>
            <source>Ann Pharmacother</source>
            <year>2015</year>
            <month>Jul</month>
            <volume>49</volume>
            <issue>7</issue>
            <fpage>808</fpage>
            <page-range>808-17</page-range>
            <pub-id pub-id-type="pmid">25907529</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17687.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Keks</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Hope</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Keogh</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Switching and stopping antidepressants.</article-title>
            <source>Aust Prescr</source>
            <year>2016</year>
            <month>Jun</month>
            <volume>39</volume>
            <issue>3</issue>
            <fpage>76</fpage>
            <page-range>76-83</page-range>
            <pub-id pub-id-type="pmid">27346915</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17687.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Denee</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Kerr</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Ming</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Wood</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Tritton</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Middleton-Dalby</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Massey</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Desai</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Current treatments used in clinical practice for major depressive disorder and treatment resistant depression in England: A retrospective database study.</article-title>
            <source>J Psychiatr Res</source>
            <year>2021</year>
            <month>Jul</month>
            <volume>139</volume>
            <fpage>172</fpage>
            <page-range>172-178</page-range>
            <pub-id pub-id-type="pmid">34077893</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17687.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cuijpers</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Dekker</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Hollon</surname>
                <given-names>SD</given-names>
              </name>
              <name>
                <surname>Andersson</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Adding psychotherapy to pharmacotherapy in the treatment of depressive disorders in adults: a meta-analysis.</article-title>
            <source>J Clin Psychiatry</source>
            <year>2009</year>
            <month>Sep</month>
            <volume>70</volume>
            <issue>9</issue>
            <fpage>1219</fpage>
            <page-range>1219-29</page-range>
            <pub-id pub-id-type="pmid">19818243</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17687.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nierenberg</surname>
                <given-names>AA</given-names>
              </name>
              <name>
                <surname>Ostacher</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Huffman</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Ametrano</surname>
                <given-names>RM</given-names>
              </name>
              <name>
                <surname>Fava</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Perlis</surname>
                <given-names>RH</given-names>
              </name>
            </person-group>
            <article-title>A brief review of antidepressant efficacy, effectiveness, indications, and usage for major depressive disorder.</article-title>
            <source>J Occup Environ Med</source>
            <year>2008</year>
            <month>Apr</month>
            <volume>50</volume>
            <issue>4</issue>
            <fpage>428</fpage>
            <page-range>428-36</page-range>
            <pub-id pub-id-type="pmid">18404015</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17687.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Beach</surname>
                <given-names>SR</given-names>
              </name>
              <name>
                <surname>Kostis</surname>
                <given-names>WJ</given-names>
              </name>
              <name>
                <surname>Celano</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Januzzi</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Ruskin</surname>
                <given-names>JN</given-names>
              </name>
              <name>
                <surname>Noseworthy</surname>
                <given-names>PA</given-names>
              </name>
              <name>
                <surname>Huffman</surname>
                <given-names>JC</given-names>
              </name>
            </person-group>
            <article-title>Meta-analysis of selective serotonin reuptake inhibitor-associated QTc prolongation.</article-title>
            <source>J Clin Psychiatry</source>
            <year>2014</year>
            <month>May</month>
            <volume>75</volume>
            <issue>5</issue>
            <fpage>e441</fpage>
            <page-range>e441-9</page-range>
            <pub-id pub-id-type="pmid">24922496</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17687.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Shea</surname>
                <given-names>ML</given-names>
              </name>
              <name>
                <surname>Garfield</surname>
                <given-names>LD</given-names>
              </name>
              <name>
                <surname>Teitelbaum</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Civitelli</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Mulsant</surname>
                <given-names>BH</given-names>
              </name>
              <name>
                <surname>Reynolds</surname>
                <given-names>CF</given-names>
              </name>
              <name>
                <surname>Dixon</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Dor&#x000e9;</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Lenze</surname>
                <given-names>EJ</given-names>
              </name>
            </person-group>
            <article-title>Serotonin-norepinephrine reuptake inhibitor therapy in late-life depression is associated with increased marker of bone resorption.</article-title>
            <source>Osteoporos Int</source>
            <year>2013</year>
            <month>May</month>
            <volume>24</volume>
            <issue>5</issue>
            <fpage>1741</fpage>
            <page-range>1741-9</page-range>
            <pub-id pub-id-type="pmid">23358607</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17687.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Montgomery</surname>
                <given-names>SA</given-names>
              </name>
            </person-group>
            <article-title>Safety of mirtazapine: a review.</article-title>
            <source>Int Clin Psychopharmacol</source>
            <year>1995</year>
            <month>Dec</month>
            <volume>10 Suppl 4</volume>
            <fpage>37</fpage>
            <page-range>37-45</page-range>
            <pub-id pub-id-type="pmid">8930008</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17687.r27">
          <label>27</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Detyniecki</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Do Psychotropic Drugs Cause Epileptic Seizures? A Review of the Available Evidence.</article-title>
            <source>Curr Top Behav Neurosci</source>
            <year>2022</year>
            <volume>55</volume>
            <fpage>267</fpage>
            <page-range>267-279</page-range>
            <pub-id pub-id-type="pmid">34241816</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17687.r28">
          <label>28</label>
          <element-citation publication-type="book">
            <chapter-title>Nefazodone</chapter-title>
            <source>LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]</source>
            <publisher-name>National Institute of Diabetes and Digestive and Kidney Diseases</publisher-name>
            <publisher-loc>Bethesda (MD)</publisher-loc>
            <year>2020</year>
            <month>3</month>
            <day>6</day>
            <pub-id pub-id-type="pmid">31643507</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17687.r29">
          <label>29</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Haria</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Fitton</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>McTavish</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Trazodone. A review of its pharmacology, therapeutic use in depression and therapeutic potential in other disorders.</article-title>
            <source>Drugs Aging</source>
            <year>1994</year>
            <month>Apr</month>
            <volume>4</volume>
            <issue>4</issue>
            <fpage>331</fpage>
            <page-range>331-55</page-range>
            <pub-id pub-id-type="pmid">8019056</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17687.r30">
          <label>30</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Settimo</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Taylor</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Evaluating the dose-dependent mechanism of action of trazodone by estimation of occupancies for different brain neurotransmitter targets.</article-title>
            <source>J Psychopharmacol</source>
            <year>2018</year>
            <month>Jan</month>
            <volume>32</volume>
            <issue>1</issue>
            <fpage>96</fpage>
            <page-range>96-104</page-range>
            <pub-id pub-id-type="pmid">29332554</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17687.r31">
          <label>31</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ruxton</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Woodman</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>Mangoni</surname>
                <given-names>AA</given-names>
              </name>
            </person-group>
            <article-title>Drugs with anticholinergic effects and cognitive impairment, falls and all-cause mortality in older adults: A systematic review and meta-analysis.</article-title>
            <source>Br J Clin Pharmacol</source>
            <year>2015</year>
            <month>Aug</month>
            <volume>80</volume>
            <issue>2</issue>
            <fpage>209</fpage>
            <page-range>209-20</page-range>
            <pub-id pub-id-type="pmid">25735839</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17687.r32">
          <label>32</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Scotton</surname>
                <given-names>WJ</given-names>
              </name>
              <name>
                <surname>Hill</surname>
                <given-names>LJ</given-names>
              </name>
              <name>
                <surname>Williams</surname>
                <given-names>AC</given-names>
              </name>
              <name>
                <surname>Barnes</surname>
                <given-names>NM</given-names>
              </name>
            </person-group>
            <article-title>Serotonin Syndrome: Pathophysiology, Clinical Features, Management, and Potential Future Directions.</article-title>
            <source>Int J Tryptophan Res</source>
            <year>2019</year>
            <volume>12</volume>
            <fpage>1178646919873925</fpage>
            <pub-id pub-id-type="pmid">31523132</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17687.r33">
          <label>33</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>An</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Wei</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Wu</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Intranasal Ketamine for Depression in Adults: A Systematic Review and Meta-Analysis of Randomized, Double-Blind, Placebo-Controlled Trials.</article-title>
            <source>Front Psychol</source>
            <year>2021</year>
            <volume>12</volume>
            <fpage>648691</fpage>
            <pub-id pub-id-type="pmid">34140915</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17687.r34">
          <label>34</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Spielmans</surname>
                <given-names>GI</given-names>
              </name>
              <name>
                <surname>Spence-Sing</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Parry</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Duty to Warn: Antidepressant Black Box Suicidality Warning Is Empirically Justified.</article-title>
            <source>Front Psychiatry</source>
            <year>2020</year>
            <volume>11</volume>
            <fpage>18</fpage>
            <pub-id pub-id-type="pmid">32116839</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17687.r35">
          <label>35</label>
          <element-citation publication-type="journal">
            <article-title>Drug interactions with selective serotonin reuptake inhibitors, especially with other psychotropics.</article-title>
            <source>Prescrire Int</source>
            <year>2001</year>
            <month>Feb</month>
            <volume>10</volume>
            <issue>51</issue>
            <fpage>25</fpage>
            <page-range>25-31</page-range>
            <pub-id pub-id-type="pmid">11503857</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17687.r36">
          <label>36</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Glassman</surname>
                <given-names>AH</given-names>
              </name>
              <name>
                <surname>Bigger</surname>
                <given-names>JT</given-names>
              </name>
            </person-group>
            <article-title>Cardiovascular effects of therapeutic doses of tricyclic antidepressants. A review.</article-title>
            <source>Arch Gen Psychiatry</source>
            <year>1981</year>
            <month>Jul</month>
            <volume>38</volume>
            <issue>7</issue>
            <fpage>815</fpage>
            <page-range>815-20</page-range>
            <pub-id pub-id-type="pmid">7247643</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17687.r37">
          <label>37</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zwar</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Richmond</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Bupropion sustained release. A therapeutic review of Zyban.</article-title>
            <source>Aust Fam Physician</source>
            <year>2002</year>
            <month>May</month>
            <volume>31</volume>
            <issue>5</issue>
            <fpage>443</fpage>
            <page-range>443-7</page-range>
            <pub-id pub-id-type="pmid">12043548</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17687.r38">
          <label>38</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Saffaei</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Lovett</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Rech</surname>
                <given-names>MA</given-names>
              </name>
            </person-group>
            <article-title>New-Onset Seizure in Patient Medicated With Bupropion for Smoking Cessation: A Case Report.</article-title>
            <source>J Emerg Med</source>
            <year>2020</year>
            <month>Mar</month>
            <volume>58</volume>
            <issue>3</issue>
            <fpage>e145</fpage>
            <page-range>e145-e147</page-range>
            <pub-id pub-id-type="pmid">32001124</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17687.r39">
          <label>39</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dagan</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Yager</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Severe bupropion XR abuse in a patient with long-standing bulimia nervosa and complex PTSD.</article-title>
            <source>Int J Eat Disord</source>
            <year>2018</year>
            <month>Oct</month>
            <volume>51</volume>
            <issue>10</issue>
            <fpage>1207</fpage>
            <page-range>1207-1209</page-range>
            <pub-id pub-id-type="pmid">30230570</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17687.r40">
          <label>40</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Declercq</surname>
                <given-names>PL</given-names>
              </name>
              <name>
                <surname>Eraldi</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Beuzelin</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>G&#x000e9;linotte</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Marchalot</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Bougerol</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Allorge</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Loriot</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Paret</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>M&#x000e9;garbane</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Rigaud</surname>
                <given-names>JP</given-names>
              </name>
            </person-group>
            <article-title>Severe serotonin syndrome caused by an interaction between an antidepressant and a cough syrup.</article-title>
            <source>Therapie</source>
            <year>2021</year>
            <season>May-Jun</season>
            <volume>76</volume>
            <issue>3</issue>
            <fpage>249</fpage>
            <page-range>249-252</page-range>
            <pub-id pub-id-type="pmid">32192714</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17687.r41">
          <label>41</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kroenke</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Spitzer</surname>
                <given-names>RL</given-names>
              </name>
              <name>
                <surname>Williams</surname>
                <given-names>JB</given-names>
              </name>
            </person-group>
            <article-title>The PHQ-9: validity of a brief depression severity measure.</article-title>
            <source>J Gen Intern Med</source>
            <year>2001</year>
            <month>Sep</month>
            <volume>16</volume>
            <issue>9</issue>
            <fpage>606</fpage>
            <page-range>606-13</page-range>
            <pub-id pub-id-type="pmid">11556941</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17687.r42">
          <label>42</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hengartner</surname>
                <given-names>MP</given-names>
              </name>
              <name>
                <surname>Jakobsen</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>S&#x000f8;rensen</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Pl&#x000f6;derl</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Efficacy of new-generation antidepressants assessed with the Montgomery-Asberg Depression Rating Scale, the gold standard clinician rating scale: A meta-analysis of randomised placebo-controlled trials.</article-title>
            <source>PLoS One</source>
            <year>2020</year>
            <volume>15</volume>
            <issue>2</issue>
            <fpage>e0229381</fpage>
            <pub-id pub-id-type="pmid">32101579</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17687.r43">
          <label>43</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hawton</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Bergen</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Simkin</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Cooper</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Waters</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Gunnell</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Kapur</surname>
                <given-names>N</given-names>
              </name>
            </person-group>
            <article-title>Toxicity of antidepressants: rates of suicide relative to prescribing and non-fatal overdose.</article-title>
            <source>Br J Psychiatry</source>
            <year>2010</year>
            <month>May</month>
            <volume>196</volume>
            <issue>5</issue>
            <fpage>354</fpage>
            <page-range>354-8</page-range>
            <pub-id pub-id-type="pmid">20435959</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17687.r44">
          <label>44</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>White</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Litovitz</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Clancy</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Suicidal antidepressant overdoses: a comparative analysis by antidepressant type.</article-title>
            <source>J Med Toxicol</source>
            <year>2008</year>
            <month>Dec</month>
            <volume>4</volume>
            <issue>4</issue>
            <fpage>238</fpage>
            <page-range>238-50</page-range>
            <pub-id pub-id-type="pmid">19031375</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17687.r45">
          <label>45</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Isbister</surname>
                <given-names>GK</given-names>
              </name>
              <name>
                <surname>Bowe</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>Dawson</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Whyte</surname>
                <given-names>IM</given-names>
              </name>
            </person-group>
            <article-title>Relative toxicity of selective serotonin reuptake inhibitors (SSRIs) in overdose.</article-title>
            <source>J Toxicol Clin Toxicol</source>
            <year>2004</year>
            <volume>42</volume>
            <issue>3</issue>
            <fpage>277</fpage>
            <page-range>277-85</page-range>
            <pub-id pub-id-type="pmid">15362595</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17687.r46">
          <label>46</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Murphy</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Rasmussen</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Murphy</surname>
                <given-names>NG</given-names>
              </name>
            </person-group>
            <article-title>Venlafaxine overdose treated with extracorporeal life support.</article-title>
            <source>CMAJ</source>
            <year>2021</year>
            <month>Feb</month>
            <day>01</day>
            <volume>193</volume>
            <issue>5</issue>
            <fpage>E167</fpage>
            <page-range>E167-E170</page-range>
            <pub-id pub-id-type="pmid">33526543</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17687.r47">
          <label>47</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Shepherd</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Velez</surname>
                <given-names>LI</given-names>
              </name>
              <name>
                <surname>Keyes</surname>
                <given-names>DC</given-names>
              </name>
            </person-group>
            <article-title>Intentional bupropion overdoses.</article-title>
            <source>J Emerg Med</source>
            <year>2004</year>
            <month>Aug</month>
            <volume>27</volume>
            <issue>2</issue>
            <fpage>147</fpage>
            <page-range>147-51</page-range>
            <pub-id pub-id-type="pmid">15261357</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17687.r48">
          <label>48</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Beuhler</surname>
                <given-names>MC</given-names>
              </name>
              <name>
                <surname>Spiller</surname>
                <given-names>HA</given-names>
              </name>
              <name>
                <surname>Sasser</surname>
                <given-names>HC</given-names>
              </name>
            </person-group>
            <article-title>The outcome of unintentional pediatric bupropion ingestions: a NPDS database review.</article-title>
            <source>J Med Toxicol</source>
            <year>2010</year>
            <month>Mar</month>
            <volume>6</volume>
            <issue>1</issue>
            <fpage>4</fpage>
            <page-range>4-8</page-range>
            <pub-id pub-id-type="pmid">20213217</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17687.r49">
          <label>49</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Balit</surname>
                <given-names>CR</given-names>
              </name>
              <name>
                <surname>Lynch</surname>
                <given-names>CN</given-names>
              </name>
              <name>
                <surname>Isbister</surname>
                <given-names>GK</given-names>
              </name>
            </person-group>
            <article-title>Bupropion poisoning: a case series.</article-title>
            <source>Med J Aust</source>
            <year>2003</year>
            <month>Jan</month>
            <day>20</day>
            <volume>178</volume>
            <issue>2</issue>
            <fpage>61</fpage>
            <page-range>61-3</page-range>
            <pub-id pub-id-type="pmid">12526723</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17687.r50">
          <label>50</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kaya</surname>
                <given-names>FB</given-names>
              </name>
              <name>
                <surname>Kuas</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Ozakin</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Karakilic</surname>
                <given-names>ME</given-names>
              </name>
              <name>
                <surname>Kaya</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Bradyarrhythmia due to mirtazapine overdose: A case of serious adverse event in a suicidal patient.</article-title>
            <source>Indian J Pharmacol</source>
            <year>2020</year>
            <season>Nov-Dec</season>
            <volume>52</volume>
            <issue>6</issue>
            <fpage>520</fpage>
            <page-range>520-523</page-range>
            <pub-id pub-id-type="pmid">33666194</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17687.r51">
          <label>51</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Thompson</surname>
                <given-names>JW</given-names>
              </name>
              <name>
                <surname>Ware</surname>
                <given-names>MR</given-names>
              </name>
              <name>
                <surname>Blashfield</surname>
                <given-names>RK</given-names>
              </name>
            </person-group>
            <article-title>Psychotropic medication and priapism: a comprehensive review.</article-title>
            <source>J Clin Psychiatry</source>
            <year>1990</year>
            <month>Oct</month>
            <volume>51</volume>
            <issue>10</issue>
            <fpage>430</fpage>
            <page-range>430-3</page-range>
            <pub-id pub-id-type="pmid">2211542</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17687.r52">
          <label>52</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wen</surname>
                <given-names>CC</given-names>
              </name>
              <name>
                <surname>Munarriz</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>McAuley</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Goldstein</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Traish</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>N</given-names>
              </name>
            </person-group>
            <article-title>Management of ischemic priapism with high-dose intracavernosal phenylephrine: from bench to bedside.</article-title>
            <source>J Sex Med</source>
            <year>2006</year>
            <month>Sep</month>
            <volume>3</volume>
            <issue>5</issue>
            <fpage>918</fpage>
            <page-range>918-922</page-range>
            <pub-id pub-id-type="pmid">16942536</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17687.r53">
          <label>53</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Das</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Kumar</surname>
                <given-names>N</given-names>
              </name>
            </person-group>
            <article-title>Suicidal Vilazodone Overdose Presenting as Serotonin Syndrome in a Young Woman With Major Depressive Disorder.</article-title>
            <source>Prim Care Companion CNS Disord</source>
            <year>2021</year>
            <month>Apr</month>
            <day>29</day>
            <volume>23</volume>
            <issue>3</issue>
            <pub-id pub-id-type="pmid">34000169</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17687.r54">
          <label>54</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Graudins</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Stearman</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Chan</surname>
                <given-names>B</given-names>
              </name>
            </person-group>
            <article-title>Treatment of the serotonin syndrome with cyproheptadine.</article-title>
            <source>J Emerg Med</source>
            <year>1998</year>
            <season>Jul-Aug</season>
            <volume>16</volume>
            <issue>4</issue>
            <fpage>615</fpage>
            <page-range>615-9</page-range>
            <pub-id pub-id-type="pmid">9696181</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17687.r55">
          <label>55</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Glauser</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Tricyclic antidepressant poisoning.</article-title>
            <source>Cleve Clin J Med</source>
            <year>2000</year>
            <month>Oct</month>
            <volume>67</volume>
            <issue>10</issue>
            <fpage>704</fpage>
            <page-range>704-6, 709-13, 717-9</page-range>
            <pub-id pub-id-type="pmid">11060957</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17687.r56">
          <label>56</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gillman</surname>
                <given-names>PK</given-names>
              </name>
            </person-group>
            <article-title>Monoamine oxidase inhibitors, opioid analgesics and serotonin toxicity.</article-title>
            <source>Br J Anaesth</source>
            <year>2005</year>
            <month>Oct</month>
            <volume>95</volume>
            <issue>4</issue>
            <fpage>434</fpage>
            <page-range>434-41</page-range>
            <pub-id pub-id-type="pmid">16051647</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17687.r57">
          <label>57</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Martinak</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Bolis</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Black</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>Fargason</surname>
                <given-names>RE</given-names>
              </name>
              <name>
                <surname>Birur</surname>
                <given-names>B</given-names>
              </name>
            </person-group>
            <article-title>Dextromethorphan in Cough Syrup: The Poor Man's Psychosis.</article-title>
            <source>Psychopharmacol Bull</source>
            <year>2017</year>
            <month>Sep</month>
            <day>15</day>
            <volume>47</volume>
            <issue>4</issue>
            <fpage>59</fpage>
            <page-range>59-63</page-range>
            <pub-id pub-id-type="pmid">28936010</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17687.r58">
          <label>58</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gummin</surname>
                <given-names>DD</given-names>
              </name>
              <name>
                <surname>Mowry</surname>
                <given-names>JB</given-names>
              </name>
              <name>
                <surname>Beuhler</surname>
                <given-names>MC</given-names>
              </name>
              <name>
                <surname>Spyker</surname>
                <given-names>DA</given-names>
              </name>
              <name>
                <surname>Bronstein</surname>
                <given-names>AC</given-names>
              </name>
              <name>
                <surname>Rivers</surname>
                <given-names>LJ</given-names>
              </name>
              <name>
                <surname>Pham</surname>
                <given-names>NPT</given-names>
              </name>
              <name>
                <surname>Weber</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>2020 Annual Report of the American Association of Poison Control Centers' National Poison Data System (NPDS): 38th Annual Report.</article-title>
            <source>Clin Toxicol (Phila)</source>
            <year>2021</year>
            <month>Dec</month>
            <volume>59</volume>
            <issue>12</issue>
            <fpage>1282</fpage>
            <page-range>1282-1501</page-range>
            <pub-id pub-id-type="pmid">34890263</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17687.r59">
          <label>59</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dwight-Johnson</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Unutzer</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Sherbourne</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Tang</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Wells</surname>
                <given-names>KB</given-names>
              </name>
            </person-group>
            <article-title>Can quality improvement programs for depression in primary care address patient preferences for treatment?</article-title>
            <source>Med Care</source>
            <year>2001</year>
            <month>Sep</month>
            <volume>39</volume>
            <issue>9</issue>
            <fpage>934</fpage>
            <page-range>934-44</page-range>
            <pub-id pub-id-type="pmid">11502951</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17687.r60">
          <label>60</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Aikens</surname>
                <given-names>JE</given-names>
              </name>
              <name>
                <surname>Kroenke</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Swindle</surname>
                <given-names>RW</given-names>
              </name>
              <name>
                <surname>Eckert</surname>
                <given-names>GJ</given-names>
              </name>
            </person-group>
            <article-title>Nine-month predictors and outcomes of SSRI antidepressant continuation in primary care.</article-title>
            <source>Gen Hosp Psychiatry</source>
            <year>2005</year>
            <season>Jul-Aug</season>
            <volume>27</volume>
            <issue>4</issue>
            <fpage>229</fpage>
            <page-range>229-36</page-range>
            <pub-id pub-id-type="pmid">15993253</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17687.r61">
          <label>61</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Brown</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Battista</surname>
                <given-names>DR</given-names>
              </name>
              <name>
                <surname>Bruehlman</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Sereika</surname>
                <given-names>SS</given-names>
              </name>
              <name>
                <surname>Thase</surname>
                <given-names>ME</given-names>
              </name>
              <name>
                <surname>Dunbar-Jacob</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Beliefs about antidepressant medications in primary care patients: relationship to self-reported adherence.</article-title>
            <source>Med Care</source>
            <year>2005</year>
            <month>Dec</month>
            <volume>43</volume>
            <issue>12</issue>
            <fpage>1203</fpage>
            <page-range>1203-7</page-range>
            <pub-id pub-id-type="pmid">16299431</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17687.r62">
          <label>62</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Akincigil</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Bowblis</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>Levin</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Walkup</surname>
                <given-names>JT</given-names>
              </name>
              <name>
                <surname>Jan</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Crystal</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Adherence to antidepressant treatment among privately insured patients diagnosed with depression.</article-title>
            <source>Med Care</source>
            <year>2007</year>
            <month>Apr</month>
            <volume>45</volume>
            <issue>4</issue>
            <fpage>363</fpage>
            <page-range>363-9</page-range>
            <pub-id pub-id-type="pmid">17496721</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17687.r63">
          <label>63</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gilbody</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Bower</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Fletcher</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Richards</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Sutton</surname>
                <given-names>AJ</given-names>
              </name>
            </person-group>
            <article-title>Collaborative care for depression: a cumulative meta-analysis and review of longer-term outcomes.</article-title>
            <source>Arch Intern Med</source>
            <year>2006</year>
            <month>Nov</month>
            <day>27</day>
            <volume>166</volume>
            <issue>21</issue>
            <fpage>2314</fpage>
            <page-range>2314-21</page-range>
            <pub-id pub-id-type="pmid">17130383</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
